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Summary
3-Halo-4,5-dihydroisoxazoles are attractive warheads
for the selective inhibition of nucleophilic active sites
in biological systems. A series of 3-bromo-4,5-dihy-
droisoxazole compounds were prepared and tested
for their ability to irreversibly inhibit human transglu-
taminase 2 (TG2), an enzyme that plays an important
role in the pathogenesis of diverse disorders includ-
ing Celiac Sprue and certain types of cancers. Several
compounds showed high specificity for human TG2
(kinh/KI > 2000 min−1M−1) but essentially no reactivity
(k < 1 min−1M−1) toward physiological thiols such as
glutathione. The pharmacokinetic and pharmacody-
namic properties of a prototype dihydroisoxazole in-
hibitor, 1b, were evaluated; in mice the compound
showed good oral bioavailability, short serum half-life
and efficient TG2 inhibition in small intestinal tissue,
and low toxicity. It also showed excellent synergism
with N,N-bis(2-chloroethyl)-N-nitrosourea (BCNU, car-
mustine) against refractory glioblastoma tumors in
mice. A fluorescent dihydroisoxazole inhibitor 5 facili-
tated microscopic visualization of TG2 endocytosis
from the extracellular surface of HCT-116 cells. To-
gether, these findings demonstrate the promise of di-
hydroisoxazole compounds as probes for the biology
of TG2 and its role in human disease.
Introduction
Tissue transglutaminase (also called transglutaminase
2 [TG2]) is a calcium-dependent enzyme that catalyzes
crosslinking between selected glutamine γ-carboxamide
groups and lysine -amino groups in proteins [1–3]. TG2
is ubiquitously expressed in different types of tissues
and is reported to have extracellular as well as intracel-
lular functions. Outside the cell TG2 anchors onto the
extracellular matrix, crosslinks fibronectin and related
proteins, and is thereby involved in cell movement, ad-*Correspondence: khosla@stanford.edu
6 Present address: Department of Chemistry, Korea University,
Seoul, 136-701, Republic of Korea.hesion, and proliferation. Intracellular TG2 loses en-
zyme activity when bound to GTP, but functions as a
G protein in the phospholipase C signal transduction
cascade. TG2 has considerable pharmacological sig-
nificance, as it is believed to play a crucial role in the
pathogenesis of diverse human disorders [4], including
Celiac Sprue, neurological disorders such as Hunting-
ton’s, Alzheimer’s, and Parkinson’s diseases, and certain
types of cancers. The medicinal attractiveness of this
protein target is underscored by the observation that
TG2 knockout mice are normal, lacking developmental,
physiological, or reproductive defects. Indeed, when
TG2 knockout mice are crossed with Huntington’s dis-
ease-prone R6/1 mice, the resulting hybrids exhibit re-
duced neuronal cell death and prolonged survival [5].
Thus, given the fundamental and practical interest in
TG2 biology, the development of small molecule inhibi-
tors capable of modulating its function in cell-based
assays, animals, and eventually humans would be de-
sirable. Here we describe the synthesis, in vitro activity,
and in vivo evaluation of a class of inhibitors with con-
siderable potential for such studies.
The catalytic mechanism of TG2 is similar to that em-
ployed by cysteine proteases, involving a catalytic triad
of cysteine, histidine, and aspartate. The cysteine thiol
group reacts with a glutamyl substrate to form a re-
active thioester intermediate, from which the acyl group
is transferred to an amine substrate (Figure 1). Several
electrophilic functional groups have been used as war-
heads to inactivate cysteine-dependent enzymes by
covalent modification of an active thiol group [6–11].
One heterocyclic compound used as an irreversible in-
hibitor of transglutaminases is 3-halo-4,5-dihydroisoxa-
zole, which is the reactive moiety of acivicin, a naturally
occurring glutamine analog with low in vivo toxicity.
Previous work has shown that decarboxylated acivicin
derivatives (1) are potent inhibitors of bovine epidermal
transglutaminase [11]. As part of our ongoing efforts to
develop dihydroisoxazole-based TG2 inhibitors [12], we
have synthesized analogs of compound 1. Here we re-
port their structure-activity relationships against human
TG2. We also demonstrate that a lead compound from
this series sensitizes tumor cell lines toward clinically
relevant proapoptotic agents, is well tolerated in rodents,
and shows excellent synergism with N,N#-bis(2-chloro-
ethyl)-N-nitrosourea (BCNU, carmustine) against refrac-
tory glioblastoma tumors in mice.
Results
Structure-Activity Relationships
Synthesis and TG2 Inhibitory Activity
of Dihydroisoxazole Inhibitors
Compound 1 and its analogs (Table 1) were prepared
by coupling suitably functionalized amino acids using
standard carbodiimide chemistry to 3-bromo-5-amino-
methyl-4,5-dihydroisoxazole or 3-bromo-5-methylamino-
methyl-4,5-dihydroisoxazole (Figure 2), which in turn
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Figure 1. The Enzymatic Action of TG2 and Chemical Structures of T
the TG2 Inhibitors t
See text for details. t
g
b
iwere synthesized by [3+2] cycloaddition of bromonitrile
oxide with corresponding allyl amines [13]. Using the t
Dsame cycloaddition reaction, compound 2a was pre-
pared directly from the corresponding allyl ester. t
tPrepared dihydroisoxazole compounds were assayed
against recombinant human TG2 using an enzyme cou- w
spled assay [14, 15], where glutamate dehydrogenase
was used to couple ammonium ion, a product of the r
eTG2-catalyzed reaction, to α-ketoglutarate to yield glu-
tamate and the simultaneous oxidation of NADH to i
NAD+ was monitored at 340 nm to follow the reaction
progress. All the tested compounds exhibited time- s
wdependent inactivation of TG2 and kinetic parameters
were obtained by plotting the reaction progress curve b
dagainst theoretical equations of the irreversible inhibi-
tion model (Figure 3) [12]. p
yThe assay results showed that compounds 1a and
1b are also reasonably active against human TG2, al- o
hthough their specificity (kinh/KI) is significantly less than
the reported values against bovine epidermal transglu- d
itaminase [11]. Several analogs were prepared to assess
the structure-activity relationships of 1. Changing the z
Hbulky benzyloxycarbonyl (Cbz) group on the α-amino
group to a small acetyl group (3a) decreased the inhibi- i
ation activity. Similar results were observed when the
secondary amide group connecting the dihydroisoxa- t
zole ring to the rest of the molecule was replaced with
an ester or a tertiary amide group in compounds 2a and B
A2b, respectively. Based on these results, the Cbz and
amide groups were fixed and the side chain of the S
samino acid moiety was varied using different amino
acids (1c–1i). The analog derived from tryptophan or c
Lγ-substituted aspartic acid retained potent inhibition
activity against TG2 while the alanine or D-phenylanine s
dderivatives exhibited significantly reduced activity. The
assay results for this series of compounds indicate that o
athe bulky side chain and its stereochemistry are impor-
tant for the inhibitor activity. In another series of com- t
1pounds (3b–3f) with different aryl carbamate groups, KI
decreased at least 5-fold compared with 1b and dioxo- i
tbenzothiophenyl derivative 4 showed the most promis-
ing inhibition activity. iigure 2. Synthesis of Dihydroisoxazole Derivatives
ee text for details.eactivity of Dihydroisoxazole Inhibitors toward
lternative Physiological Nucleophiles
he stability of the 3-bromo-4,5-dihydroisoxazole group,
he electrophile responsible for the irreversible inhibi-
ion, was tested against a representative cysteine thiol
roup. The reduced form of glutathione (GSH) is proba-
ly the most abundant physiological thiol (around 5 mM
n animal cells) with a pKa value (8.66). When the solu-
ion of 1b (0.1 mM in a 200 mM MOPS buffer with 3.3%
MSO) was monitored using HPLC for 9 hr of incuba-
ion with 5 mM GSH at pH 7.2, no changes were de-
ected in the concentration of 1b and the same result
as observed at pH 9.0. This finding (k < 1 min−1M−1)
uggests that the dihydroisoxazole warhead is likely to
etain reasonable stability in physiological systems,
ven at a pH where some amount of the thiol is present
n the thiolate form.
Other dihydroisoxazole compounds tested showed
imilar stabilities with 1b except compounds 3f and 4,
hich have a dioxobenzothiophene group. When incu-
ated with 5 mM GSH at pH 7.2, the latter compounds
ecomposed almost completely within 10 min to multi-
le products, which have not been characterized fully
et. No decomposition was observed in solutions with-
ut the thiol added. An analog of compound 3f, which
as a tyrosine methyl ester group instead of the dihy-
roisoxazole methyl amide, also decomposed quickly
n the presence of GSH confirming that the dioxoben-
othiophene group is responsible for the instability.
owever, this control compound has insignificant TG2
nhibition activity, suggesting that the TG2 inhibitory
ctivities of 3f and 4 are not correlated with their reac-
ivity toward simple nucleophiles.
iology of Dihydroisoxazole Inhibitors
ctivity of 1b against Tumor Cell Lines in Culture
tudies with competitive TG2 substrate analogs have
hown that inhibition of TG2 sensitizes certain tumor
ells to death induced by proapoptotic agents ([16],
.Y. et al., unpublished data). To demonstrate chemo-
ensitization activity of the dihydroisoxazole inhibitors
escribed in this report, a cell-based assay was devel-
ped using HCT-116, a human colon cancer cell line,
nd epothilone C, a member of a promising class of
ubulin binding anticancer agents (see for example [17–
9]). As shown in Figure 4, incubation of HCT-116 with
ncreasing levels of 1b in the 1–100 µM range reduced
he GI50 for epothilone C by >2-fold. When used by
tself, no cytotoxicity was observed for 1b at concentra-
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471Table 1. Dissociation Constants (KI) and Inhibition Rate Constants (kinh) of Dihydroisoxazole Inhibitors of Human TG2
KI (mM) kinh (min−1) kinh/KI (min−1M−1)
1a R = CH2C6H5 0.74 1.3 1900
1b CH2C6H4-p-OH 0.42 0.86 2000
1c CH2C6H4-p-F 0.43 0.42 980
1d CH2C6H4-m-F 0.39 0.84 2200
1e CH2-3-(5-OH-indolyl) 0.31 0.78 2500
1f CH2-3-(5-OH-indolyl) 0.11 0.31 2800
1g CH2CONHCH2Ph 0.24 0.54 2300
1h (R)-CH2Ph 0.31 0.29 940
1i CH3 0.91 0.41 450
2a X = O 1.3 0.32 230
2b NCH3 0.26 0.19 730
3a X = H, R = Me 2.7 0.60 220
3b X = OH, R = O-4-picolyl 0.081 0.12 1500
3c O-3-picolyl 0.078 0.21 2700
3d OCH2CH2Ph 0.061 0.093 1500
3e O-2-naphthyl 0.043 0.070 1600
3f 0.087 0.38 1400
4 R = CH2-3-(5-OH-indolyl) 0.079 0.54 6800tions below 100 M. Similar findings have also been
observed (data not shown) using the U87 glioblastoma
cell line and the clinically important cytotoxic agent
BCNU [20].
Pharmacokinetics, Pharmacodynamics,
and Bioavailability of 1b in Mice
Preliminary experiments with mice showed that com-
pound 1b has sufficient solubility, stability, and bio-
availability for further in vivo studies. Collected serum
samples were extracted with ethyl acetate and the sep-
arated organic layer was analyzed using analytical
HPLC or LC-MS. Serum levels were calculated using a
calibration curve. When injected intraperitoneally, the
concentration of 1b in serum samples collected 5 min
after injection was 11 and 24 M for 20 and 40 mg/kg
dosages, respectively. At the higher dose, the serum
concentration dropped to 11 M after 10 min, and be-
low the lower limit of quantitation (3 M) after 30 min.
Together, these results demonstrate that compound 1b
can maintain a pharmacologically useful concentration
in serum in a dose-dependent manner, and that it has
a relatively short half-life in serum. No metabolites
could be reliably detected.Figure 3. Enzyme Inhibition by an Irreversible Inhibitor
E, S, P, and I are enzyme, substrate, product, and inhibitor, respec-
tively.Our interest in pharmacologically useful TG2 inhibi-
tors is especially motivated by their potential utility for
treating Celiac Sprue, a widespread disorder of the
small intestine for which no pharmacologic therapy is
currently available (see for example [21–23]). For this
application, an inhibitor with a short serum half-life is
desirable so that the compound, when dosed orally, is
primarily localized to the diseased organ (the small in-
testine). At the same time, the TG2 inhibitor must also
have adequate bioavailability so that it can penetrate
into the intestinal lamina propria, the primary location
of pathologically relevant TG2 [24]. To estimate the oral
bioavailability of 1b, the compound was dosed orally in
mice at 80 mg/kg. Blood samples were collected 30Figure 4. Effect of TG2 Inhibitor 1b on GI50 for Epothilone C
The error bars represent data from assays performed four times
with eight individual measurements for each condition.
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472min and 1 hr after oral gavage, and the concentration
of 1b was measured. At both time points, the observed
serum concentrations were 5.5 M and 4.7 M, respec-
tively, demonstrating good oral bioavailability of the
compound.
The attractive bioavailability characteristics of com-
pound 1b prompted us to measure its inhibitory effect
on TG2 in the small intestinal tissue. Mice were given a
single oral dose of vehicle (40% DMSO), 40 mg/kg 1b,
or 60 mg/kg 1b. After 4 hr the animals were sacrificed
and specific TG2 activity was measured in proximal
small intestinal tissue (the primary site of Celiac Sprue
lesions in humans), as described in the Experimental
Procedures. The average TG2 specific activities were
43 pmol/mg-min, 14 pmol/mg-min, and 8 pmol/mg-min
(average of two mice), respectively, indicating that F
wdose-dependent inhibition could be achieved in the
small intestine. T
cSafety of 1b in Mice
cTo assess potential drug toxicity caused by long-term
ddosing, mice were injected daily with 1b (i.p., 40 mg/
m
kg) or vehicle (40% DMSO) for 14 days. All five inhibitor-
treated mice survived the regimen without significant
weight loss or gross toxicity. Serum samples were ana-
plyzed after the final dose using standard hepatic en-
azyme and bilirubin assays. Alkaline phosphatase (ALP)
wand bilirubin levels were not statistically different be-
itween the groups of mice treated with 1b or vehicle
bonly (ALP, 98 ± 42 versus 146 ± 9 U/l; bilirubin, 0.16 ±
T0.11 versus 0.13 ± 0.07 mg/dl), whereas the level of ala-
onine aminotransferase was elevated in the inhibitor-
ctreated mice (360 ± 122 versus 79 ± 45 U/l). These re-
lsults suggest that mice can tolerate relatively high
tsystemic doses of a dihydroisoxazole inhibitor such as
1b for at least 2 weeks. Elevated liver enzyme levels
Dsuggest that hepatic tissue is a potential primary site
of the dose-limiting effects of compound 1b.
HChemosensitization of Refractory Glioblastoma
pTumors by 1b in Mice
3Based on the good safety and in vitro efficacy of 1b,
iwe were prompted to evaluate its ability to enhance the
usensitivity of chemotherapy against refractory tumors
iin animals. Balb/C mice were injected subcutaneously
with 2 × 106 syngeneic DBT glioblastoma cells, and tu- t
mors were allowed to establish for 1 week [25–27]. Mice o
were then treated with daily intraperitoneal injections
with either vehicle or TG2 inhibitor starting on day 8 for
10 treatments. On day 10 and 12, mice were coinjected
with vehicle or BCNU (10 mg/kg and 5 mg/kg, respec-
tively). This dosage schedule of BCNU results in mini-
mal effect on the DBT tumors in this experimental para-
digm. Tumors were removed and weighed 3 weeks after
start of the experiment, and the mean tumor weight
was separately calculated for each cohort. The results,
summarized in Figure 5, demonstrate excellent dose-
dependent efficacy of 1b.
Visualizing the Action of Dihydroisoxazole
Inhibitors on Cells
TG2 is found in various tissues and subcellular loca-
tions. To understand the biological and pathogenic
roles of this ubiquitous enzyme, small molecule agents
are needed to visualize its spatial distribution and tem- F
Cporal dynamics. Toward this goal a fluorescent (dansyl)
dihydroisoxazole analog 5 was synthesized. The com- Kigure 5. Weights of DBT Glioblastoma Xenografts after Treatment
ith BCNU Alone or in Combination with TG2 Inhibitor 1b
he decrease in mean tumor weight in the groups treated with
ombination 1b and BCNU was significantly different from both the
ontrol and the BCNU groups as assessed with a two-tailed Stu-
ent’s t test for independent variables. Significance was deter-
ined with P < 0.05.ound has absorption and emission maxima at 350 nm
nd 550 nm, respectively. Treatment of HCT-116 cells
ith 50 M of analog 5 for 1 hr resulted in strong label-
ng of the cell plasma membrane, together with weaker
ut distinct granular labeling of the cytosol (Figure 6).
he former pattern presumably reflects the abundance
f TG2 anchored in the extracellular matrix of HCT-116
ells, whereas granular intracellular staining may be re-
ated to its presence in secretory granules or to a po-
ential receptor-mediated endocytotic process.
iscussion
uman TG2 is a structurally and mechanistically com-
lex protein [28] with multiple biological functions [1–
]. It is an especially interesting medicinal target, since
t plays a crucial role in the pathogenesis of several
nrelated disorders, yet it appears to be nonessential
n mammals. Consequently, small molecule inhibitors of
his enzyme can be useful probes not just for TG2 biol-
gy but also its role in a variety of diseases. Here weigure 6. Two-Photon Confocal Microscopic Image of HCT-116
ells Incubated with Fluorescent Dihydroisoxazole Compound 5
= 0.11 mM, k = 0.037 min−1, k /K = 340 min−1M−1.I inh inh I
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473have analyzed the structure-activity relationships of di-
hydroisoxazole inhibitors of human TG2 and investi-
gated the properties of a lead compound in vitro and
in vivo.
A series of compounds with variations at three dif-
ferent positions have been prepared and tested to ex-
amine the relationship between the molecular structure
and the inhibition properties. Based on their inhibitory
activities, together with each compound’s stability and
solubility in aqueous solutions, one of the compounds
was selected for further investigations into the biologi-
cal properties of the dihydroisoxazole inhibitors. The
pharmacological significance of TG2 in glioblastoma
survival and resistance to chemotherapy has recently
been highlighted (L.Y. et al., unpublished data). In vitro
studies validated the hypothesis that TG2 inhibitors,
while nontoxic by themselves, can sensitize tumor cells
to modulation by other pharmacological agents. For ex-
ample, tumor cell lines that are ordinarily refractory to-
ward cytotoxic agents such as epothilone and BCNU
can be sensitized by pretreatment with dihydroisoxa-
zole inhibitors of TG2. Importantly, this chemo-sensiti-
zation ability of dihydroisoxazole 1b was validated in
mice harboring refractory glioblastoma tumors. Gli-
oblastomas are notoriously resistant to standard clin-
ical treatment protocols with radiation and chemother-
apy. The mean survival in patients diagnosed with
glioblastomas is about 12 months and has failed to im-
prove over the years, despite modern neurosurgical
procedures, sophisticated conformal radiation tech-
niques, and multiple attempts with chemotherapy regi-
mens. Given the acute need for defining new treatment
strategies in glioblastoma patients, dihydroisoxazole
inhibitors such as the compounds reported here could
be used to evaluate the incremental benefit of blocking
TG2 in conjunction with standard radiotherapeutic or
chemotherapeutic protocols.
Our preliminary studies with dihydroisoxazole 1b in
mice have also highlighted several potentially attractive
characteristics of this class of compounds for chronic
disorders in which TG2 is believed to play a role. For
example, Celiac Sprue is a widespread inflammatory
disease characterized by malabsorption, abnormal
small-intestinal structure, and intolerance to gluten, a
complex mixture of nutritionally important proteins
found in common dietary foodgrains such as wheat,
rye, and barley [21–23]. Since gluten is an unlabeled
ingredient in many packaged, bottled, and canned
foods, a strict gluten-exclusion diet is very difficult to
maintain and there is urgent need for therapeutic op-
tions. Although ex vivo studies with intestinal biopsy
tissue from Celiac Sprue patients have demonstrated a
critical role for TG2 in gluten-induced pathogenesis
[29], the absence of an animal model for this wide-
spread disease underscores the need for a suitable ex-
perimental therapeutic agent to validate TG2 as a ther-
apeutic target for Celiac Sprue. In addition to potency
and selectivity, such a small molecule would be orally
bioavailable, have short serum half-life so as to mini-
mize systemic distribution, and be well tolerated for
the duration of a controlled, proof-of-principle clinical
study (2–4 weeks). Our findings demonstrate that 1b
has many of these properties. Over a 2 week period of
high-dose daily administration, it revealed a potentialfor hepatotoxicity based on elevation of serum trans-
aminase levels without a significant effect on alkaline
phosphatase or bilirubin. Further studies would be re-
quired to assess whether this is an intrinsic property of
all TG2 inhibitors or whether it reflects non-mechanism-
associated toxicity of 1b.
Significance
We have investigated a series of dihydroisoxazole
compounds for their potential inhibition activities
against human TG2 and identified one of the com-
pounds as a lead compound. In vivo experiments
showed that this inhibitor is orally bioavailable, non-
toxic, and active in animal models. This compound
showed synergic effects to enhance chemosensitivity
of tumor cells toward cytotoxic reagents. In addition
to the potential therapeutic relevance of dihydroisox-
azole inhibitors of human TG2, such compounds also
offer the potential to provide fundamentally new and
mechanistically fascinating insights into cell biology.
A plethora of functions have been suggested for this
multidomain protein in the context of the extracellular
matrix, cytosol, and mitochondria; this is further com-
plicated by the absence of a signal sequence en-
coded within the TG2 gene [1–4]. Most recent investi-
gations into TG2 biology have relied upon the use of
competitive substrate analogs such as cystamine and
monodansyl cadaverine (see for examples [30–32]).
By virtue of their dual advantage of specificity and
spectroscopic characteristics, fluorescent dihydro-
isoxazole inhibitors such as 5 could be used to shed
light on many unanswered questions about this most
remarkable enzyme.
Experimental Procedures
TG2 Inhibition Assay
Recombinant human TG2 was expressed in E. coli and purified to
>90% homogeneity as before [14]. Compounds were assayed in a
reaction mixture containing 200 mM MOPS (pH = 7.2), 5 mM CaCl2,
1 mM EDTA, 10 mM α-ketoglutarate, 18 U/ml glutamate dehydroge-
nase, 0.4 mM NADH, 3.3% (v/v) DMSO, 0.5 M TG2, and 2, 5, or
10 mM Cbz-Gln-Gly,Na (KM = 11 mM, kcat = 37 min−1). The enzyme
reaction was started by addition of TG2 and the consumption of
NADH was monitored by UV spectroscopy (340 nm,  = 6220
cm−1M−1). Kinetic parameters were obtained by plotting the reac-
tion progress curve against theoretical equations for irreversible
enzyme inhibition [12].
HCT-116 Cell Growth Inhibition Assay
HCT-116 cells were grown in RPMI medium 1640 supplemented
with 10% (vol/vol) FCS, 2 mM glutamine, 100 units/ml penicillin,
and 100 units/ml streptomycin. Cells were grown for 24 hr at 37°C
and 5% CO2 in air in a humidified incubator at 10,000 cells/well,
and were then exposed to varying concentrations of 1b (0–100 M)
for 24 hr. The media with inhibitor was then replaced with media
containing epothilone C (0–4 M) and incubated for an additional
24 hr. Viable cells were then measured using the MTT assay. For
this, 10 l of a 5 mg/ml MTT stock solution in PBS was added per
100 l of media, and incubated with the cells for 2 hr at 37°C. The
media and MTT solution were then removed by aspiration and the
cells were solubilized in DMSO and transferred to a 96-well plate,
and the absorbance was read at 570 nm by use of a Molecular
Devices SpectraMax 190 96-well plate reader. The assay was per-
formed four times with eight individual measurements for each
condition.
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C3H mice (2–5 months old) were given the TG2 or carrier alone then
euthanized by CO2 inhalation. Blood was collected by intracardiac
puncture followed by analysis of serum for alkaline phosphatase
(U/l), total bilirubin (mg/dl), and alanine aminotransferase (U/l).
Measurement of TG2 Activity in the Small Intestine Tissue
Immediately after sacrificing each mouse, approximately 15–20 cm
of intestine distal to the ligament of Treitz was excised, wrapped in
parafilm, and immediately frozen on dry ice. The intestines were
then transferred to a −80°C freezer for storage. Before thawing,
they were weighed, diced into small pieces using a razor, and thor-
oughly rinsed with water using a squeeze bottle. They were then
dounced in 50 mM mannitol, 2 mM Tris-HCl, 10 mM calcium chlo-
ride (pH = 7.1) at 4°C to give a 20% homogenate.
The incorporation of [1,414C]-putrescine (Amersham Biosci-
ences) into N,N-dimethyl casein (Sigma-Aldrich Co.) was based
upon a modification [33] to the filter paper method of Lorand [34].
The assay was initiated by adding 80 l homogenate to 320 l
1substrate buffer (83 mM dithiothreitol, 83 mM Tris-HCl, 16.7 mM
calcium chloride, 4.17 mg/ml N,N-dimethyl casein [pH = 9.0], and
0.167% Triton X-100) prewarmed to 37°C. The reaction mixture was
then incubated at 37°C, and 30 l was spotted on dry 3-MM What-
man chromatography paper (1 in × 1 in) presoaked in a 10% solu-
1tion of trichloroacetic acid (TCA) and immediately plunged into
10% TCA to precipitate the protein. Each filter paper was soaked
15 min in 10% TCA, 15 min in 5% TCA two times, 3 min in 50%
ethanol/50% acetone, and 2 min in acetone. The filter papers were
1air dried, placed in 5 ml Ready Safe Scintillation Cocktail (Beckman
Coulter), and counted on a Beckman LS 3801 liquid scintillation
counter. Time points were taken every 15 min for an hour and the
reaction rate was calculated using linear regression. Each point
1was measured in duplicate, and nonwashed samples were used to
quantify the amount of putrescine incorporated. Protein concentra-
tions were determined using the Bio-Rad protein assay.
1
Glioblastoma Mouse Tumor Model
Detailed procedures for these studies are described elsewhere [L.Y.
et al., unpublished data].
1
Supplemental Data
1Synthesis and characterization of compounds 1–5 is available on-
line at http://www.chembiol.com/cgi/content/full/12/4/469/DC1/.
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